Sucralfate therapy in NSAID bleeding gastropathy

Juan R. Malagelada, Arturo Rodríguez de La Serna, Hans Gert Dammann, Miquel Pons, Carlos Armas, Miquel Sala, Xavier Tena, Enrique Celdrán, Antoni Mesa

Research output: Contribution to journalArticleResearchpeer-review

8 Citations (Scopus)

Abstract

Background & Aims: A randomized, double-blind, placebo-controlled, multicenter study was conducted to assess the efficacy of 2 g sucralfate suspension in treating gastric mucosal lesions caused by long-term treatment with nonsteroidal anti-inflammatory drugs (NSAIDs). Methods: Only patients given NSAIDs continuously for at least 2 months with positive fecal occult blood (FOB) and endoscopically confirmed mild to moderate mucosal lesions (Lanza scale, grades 2-4) were included. After 1-week run-in phase, patients were stratified into 2 groups according to gastropathy-related symptoms during the preceding 7 days (symptomatic vs. asymptomatic) and randomized to 2 g (10 mL) of sucralfate suspension or placebo twice a day over a 6-week period. NSAIDs were given according to each patient's dosage schedule and always after meals. Results: Twenty-five patients received sucralfate and 25 received placebo. At the end of the study, 68% (17/25) of patients given sucralfate had no lesions (Lanza grade O) on endoscopy compared with 35% (8/23) in controls (P = 0.042). The Lanza grades in patients given sucralfate were significantly improved compared with the placebo patients (P = 0.022). Conclusions: In this target population selected according to positive FOB test and endoscopic evidence of mucosal injury, chronic administration of sucralfate significantly decreased NSAID-induced gastric erosions.
Original languageEnglish
Pages (from-to)51-56
JournalClinical Gastroenterology and Hepatology
Volume1
Issue number1
DOIs
Publication statusPublished - 1 Jan 2003

Fingerprint Dive into the research topics of 'Sucralfate therapy in NSAID bleeding gastropathy'. Together they form a unique fingerprint.

Cite this